Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)
-
摘要: 肝脏虽为“免疫特惠器官”,肝移植术后急性排斥反应发生率及严重程度明显低于其他器官移植,但术后排斥反应仍较为常见,规范的免疫抑制治疗是保证移植效果的关键。为进一步规范肝移植术后免疫抑制治疗及排斥反应诊疗,中华医学会器官移植学分会组织肝移植专家,总结国内外相关研究最新进展,并结合国际指南和临床实践,针对肝移植术后免疫抑制剂应用原则、常用方案及各类型排斥反应的诊断与治疗,制订《中国肝移植免疫抑制治疗与排斥反应诊疗规范(2019版)》。Abstract: The liver is an "immune-privileged organ". The incidence and severity of acute rejection after liver transplantation are significantly lower than those after the transplantation of other organs. However, postoperative rejection is still relatively common, and standardized immunosuppressive therapy is the key to guarantee the efficacy of transplantation. To further standardize the immunosuppressive therapy and diagnosis and treatment of rejection after liver transplantation, Branch of Organ Transplantation of Chinese Medical Association organized liver transplant experts to summarize the latest research progress at home and abroad, integrate international guidelines and clinical practice and formulate the "Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)" based upon the application principle and common regime of immunosuppressant, as well as diagnosis and treatment of various types of rejection after liver transplantation.
-
Key words:
- Liver transplantation /
- Immunosuppressive therapy /
- Transplantation immunity /
- Rejection
-
[1] HALLIDAY N, WESTBROOK RH. Liver transplantation: post-transplant management[J]. Br J Hosp Med (Lond), 2017, 78(5):278-285. DOI: 10.12968/hmed.2017.78.5.278. [2] SHAKED A, DESMARAIS MR, KOPETSKIE H, et al. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation[J]. Am J Transplant, 2019, 19(5):1397-1409. DOI: 10.1111/ajt.15205. [3] JUCAUD V, SHAKED A, DESMARAIS M, et al. Prevalence and impact of de novo donor-specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients[J]. Hepatology, 2019, 69(3):1273-1286. DOI: 10.1002/hep.30281. [4] GUO T, LEI J, GAO J, et al. The hepatic protective effects of tacrolimus as a rinse solution in liver transplantation: a Meta-analysis[J]. Medicine (Baltimore), 2019, 98(21): e15809. DOI: 10.1097/MD.0000000000015809. [5] RAYAR M, TRON C, LOCHER C, et al. Tacrolimus concentrations measured in excreted bile in liver transplant recipients: the STABILE study[J]. Clin Ther, 2018, 40(12):2088-2098. DOI: 10.1016/j.clinthera. 2018.10.015. [6] SALIBA F, ROSTAING L, GUGENHEIM J, et al. Corticosteroid-sparing and optimization of mycophenolic acid exposure in liver transplant recipients receiving mycophenolate mofetil and tacrolimus: a randomized, multicenter study[J]. Transplantation, 2016, 100(8):1705-1713. DOI: 10.1097/TP.0000000000001228. [7] GRIGG SE, SARRI GL, GOW PJ, et al. Systematic review with Meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2019, 49(10):1260-1273. DOI: 10.1111/apt.15253. [8] JUNG DH, TAK E, HWANG S, et al. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence[J]. Liver Transpl, 2018, 24(7):932-945. DOI: 10.1002/lt.25191. [9] PERITO ER, MARTINEZ M, TURMELLE YP, et al. Posttransplant biopsy risk for stable long-term pediatric liver transplant recipients: 451 percutaneous biopsies from two multicenter immunosuppression withdrawal trials[J]. Am J Transplant, 2019, 19(5):1545-1551. DOI: 10.1111/ajt.15255. [10] CASTEDAL M, SKOGLUND C, AXELSON C, et al. Steroid-free immunosuppression with low-dose tacrolimus is safe and significantly reduces the incidence of new-onset diabetes mellitus following liver transplantation[J]. Scand J Gastroenterol, 2018, 53(6):741-747. DOI: 10.1080/00365521.2018.1463390. [11] KOO J, WANG HL. Acute, chronic, and humoral rejection: pathologic features under current immunosuppressive regimes[J]. Surg Pathol Clin, 2018, 11(2):431-452. DOI: 10.1016/j.path.2018.02.011. [12] AIBARA N, OHYAMA K, HIDAKA M, et al. Immune complexome analysis of antigens in circulating immune complexes from patients with acute cellular rejection after living donor liver transplantation[J]. Transpl Immunol, 2018, 48:60-64. DOI: 10.1016/j.trim.2018.02.011. [13] LO RC, CHAN KK, LEUNG CO, et al. Expression of hepatic progenitor cell markers in acute cellular rejection of liver allografts-an immunohistochemical study[J]. Clin Transplant, 2018, 32(3):e13203. DOI: 10.1111/ctr.13203. [14] LEE M. Antibody-mediated rejection after liver transplant[J]. Gastroenterol Clin North Am, 2017, 46(2): 297-309. DOI: 10.1016/j.gtc.2017.01.005. [15] RODRÍGUEZ-PERÁLVAREZ M, RICO-JURI JM, TSOCHATZIS E, et al. Biopsy-proven acute cellular rejection as an efficacy endpoint of randomized trials in liver transplantation: a systematic review and critical appraisal[J]. Transpl Int, 2016, 29(9):961-973. DOI: 10.1111/tri.12737. [16] MCALISTER VC. Anti-donor immunoglobulin G subclass in liver transplantation[J]. Hepatobiliary Surg Nutr, 2019, 8(2):125-128. DOI: 10.21037/hbsn.2018.12.09. [17] JADLOWIEC CC, TANER T. Liver transplantation: current status and challenges[J]. World J Gastroenterol, 2016, 22(18):4438-4445. DOI: 10.3748/wjg.v22.i18.4438. [18] FENG S, BUCUVALAS JC, DEMETRIS AJ, et al. Evidence of chronic allograft injury in liver biopsies from long-term pediatric recipients of liver transplants[J]. Gastroenterology, 2018, 155(6):1838-1851. DOI: 10.1053/j.gastro.2018.08.023. [19] BITAR C, OLIVIER K, LEE C, et al. Acute graft-vs-host disease following liver transplantation[J]. Cutis, 2019, 103(6):E8-E11. [20] 马明, 蒋文涛.肝移植术后移植物抗宿主病[J/CD].实用器官移植电子杂志, 2014, 2(4): 249-252. DOI: 10.3969/j.issn.2095-5332.2014.04.012.MA M, JIANG WT. Graft versus host disease after liver transplantation[J/CD]. Prac J Organ Transplant(Electr Vers), 2014, (4): 249-252. DOI: 10.3969/j.issn.2095-5332.2014.04.012.
点击查看大图
计量
- 文章访问数: 1179
- HTML全文浏览量: 327
- PDF下载量: 348
- 被引次数: 0